Investors with the goal of beating the broader market often turn to stock selection. Strategic choices in individual stocks can have a profound impact on your wealth.
In the latest session, Cullinan Therapeutics Inc (NASDAQ: CGEM) closed at $7.4 down -5.25% from its previous closing price of $7.81. In other words, the price has decreased by -$5.25 from its previous closing price. On the day, 0.7 million shares were traded. CGEM stock price reached its highest trading level at $7.8 during the session, while it also had its lowest trading level at $7.36.
Ratios:
For a deeper understanding of Cullinan Therapeutics Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 9.83 and its Current Ratio is at 9.83. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
On October 24, 2024, UBS started tracking the stock assigning a Buy rating and target price of $30.UBS initiated its Buy rating on October 24, 2024, with a $30 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Oct 28 ’25 when Lynx1 Capital Management LP bought 165,667 shares for $8.40 per share. The transaction valued at 1,391,686 led to the insider holds 8,963,500 shares of the business.
Lynx1 Capital Management LP bought 150,000 shares of CGEM for $1,328,250 on Oct 16 ’25. The 10% Owner now owns 8,765,616 shares after completing the transaction at $8.86 per share. On Oct 15 ’25, another insider, Lynx1 Capital Management LP, who serves as the 10% Owner of the company, bought 51,500 shares for $7.94 each. As a result, the insider paid 409,049 and bolstered with 8,615,616 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CGEM now has a Market Capitalization of 437150496 and an Enterprise Value of 173187488.
Stock Price History:
The Beta on a monthly basis for CGEM is -0.06, which has changed by -0.52609223 over the last 52 weeks, in comparison to a change of 0.15566266 over the same period for the S&P500. Over the past 52 weeks, CGEM has reached a high of $17.50, while it has fallen to a 52-week low of $5.68. The 50-Day Moving Average of the stock is 4.56%, while the 200-Day Moving Average is calculated to be -7.94%.
Shares Statistics:
For the past three months, CGEM has traded an average of 866.53K shares per day and 923670 over the past ten days. A total of 59.07M shares are outstanding, with a floating share count of 36.85M. Insiders hold about 37.61% of the company’s shares, while institutions hold 78.59% stake in the company. Shares short for CGEM as of 1760486400 were 6629787 with a Short Ratio of 7.65, compared to 1757894400 on 6181110. Therefore, it implies a Short% of Shares Outstanding of 6629787 and a Short% of Float of 12.979999000000001.
Earnings Estimates
Cullinan Therapeutics Inc (CGEM) is presently subject to a detailed evaluation by 8.0 analysts, each offering their unique perspectives on its market standing.The consensus estimate for the next quarter is -$0.91, with high estimates of -$0.83 and low estimates of -$1.02.
Analysts are recommending an EPS of between -$3.31 and -$4.01 for the fiscal current year, implying an average EPS of -$3.67. EPS for the following year is -$3.62, with 7.0 analysts recommending between -$2.59 and -$4.4.
